Emisphere Technologies Inc. (EMIS) to Conduct Studies for Treatment of Osteoarthritis of the Knee
Osteoarthritis affects roughly 21 million people in the United States each year. This inflammatory affliction accounts for 25 percent of visits to primary care physicians, and represents half of all non-steroidal anti-inflammatory drug prescriptions. Osteoarthritis can be extremely painful, whether sitting or standing, as the cartilage between joints wears away. Approximately 80 percent of Americans are expected to suffer from this affliction by the time they are 65 years of age. To combat this number, Emisphere Technologies Inc. (Nasdaq: EMIS) focuses on improved delivery of therapeutic molecules through its Eligen Technology, which can be administered orally or through buccal, rectal,…